{"entity":{"id":"batch-release","kind":"term","name":"Batch release (lot disposition)","aka":["batch release","lot release","batch disposition"],"tldr":"Batch release is the documented quality decision about one lot of a product. A set of passing test results supports that decision but is not the same thing, and a released lot has not been shown to help any patient.","summary":"In the US, drug production and control records are reviewed and approved by the quality control unit before a batch is released or distributed, and any unexplained discrepancy or failure of a batch to meet a specification must be thoroughly investigated whether or not the batch has been distributed (21 CFR 211.192). The decision therefore draws on test results with their methods and acceptance criteria, manufacturing and deviation records, and the identity of the lot and product version; a certificate of analysis can summarise results but does not replace that review. FDA's 2022 guidance on out-of-specification results says the practice of repeating a test until a passing result is obtained and then disregarding the failing results without scientific justification is 'testing into compliance', which it calls unscientific and objectionable under CGMP. That guidance covers chemistry-based laboratory testing; it says it is not intended to address biological assays, so a copied retest procedure cannot be assumed to fit a cell or potency assay. A lot can be released, held pending review or rejected; a result that has not arrived is neither a pass nor a failure. Release of a lot is a quality decision, separate from regulatory authorisation of the product, from a patient's eligibility, and from evidence of clinical benefit.","asOf":"2026-11-14","links":[{"label":"21 CFR 211.192: production record review","url":"https://www.ecfr.gov/current/title-21/section-211.192"},{"label":"FDA: investigating out-of-specification test results for pharmaceutical production (May 2022)","url":"https://www.fda.gov/media/158416/download"},{"label":"FDA: quality systems approach to pharmaceutical CGMP regulations (September 2006)","url":"https://www.fda.gov/media/71023/download"},{"label":"21 CFR 211.22","url":"https://www.ecfr.gov/current/title-21/section-211.22"},{"label":"21 CFR 211.80","url":"https://www.ecfr.gov/current/title-21/section-211.80"},{"label":"21 CFR 211.84","url":"https://www.ecfr.gov/current/title-21/section-211.84"},{"label":"21 CFR 211.142","url":"https://www.ecfr.gov/current/title-21/section-211.142"},{"label":"21 CFR 610.1","url":"https://www.ecfr.gov/current/title-21/section-610.1"},{"label":"21 CFR 610.2","url":"https://www.ecfr.gov/current/title-21/section-610.2"},{"label":"FDA: final Potency Assurance for Cellular and Gene Therapy Products (November 2026 PDF)","url":"https://www.fda.gov/media/196183/download"},{"label":"FDA: final potency-assurance guidance (November 2026)","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products"},{"label":"Federal Register: final potency-assurance guidance, 3 November 2026","url":"https://www.federalregister.gov/documents/2026/11/03/2026-22427/potency-assurance-for-cellular-and-gene-therapy-products-guidance-for-industry-availability"},{"label":"FDA: vaccine CMC for licence applications (January 1999)","url":"https://www.fda.gov/media/73614/download"}],"tags":[],"related":["good-manufacturing-practice","cell-therapy-release-testing","radiopharmaceutical-gmp-release","car-t-manufacturing-process"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A lot-release decision concerns one identified batch. Good manufacturing practice concerns the quality system; cell and gene products add product-specific biological, identity and handling questions, while radiopharmaceuticals add the constraints of radioactive decay.","A lot is identified material made under a defined manufacturing record, and a specification connects named tests and methods to acceptance criteria; ICH Q6B defines a specification as a list of tests, references to analytical procedures and acceptance criteria. Release concerns that lot, not the general reputation of its manufacturer.","What a release review brings together: test results with their methods and criteria, manufacturing and deviation records, lot and version identity, and stability and handling information. In US finished-drug rules the quality control unit reviews and approves production and control records before a batch is released or distributed (21 CFR 211.192). A certificate of analysis may summarise results but does not replace that review.","Dispositions. FDA's quality-systems guidance describes the quality unit approving or rejecting materials and drug products; US regulations give the quality unit authority to approve or reject materials and drug products (21 CFR 211.22(a)); other provisions describe quarantine or withholding from use while materials or products await release (211.80(d), 211.84(a), 211.142(a)). Hold pending review is a plain-language description of that unresolved disposition. A result that has not arrived is neither a pass nor a failure. Inference lesson: a spreadsheet that reports all tests passed because it lists only completed tests has lost the missingness information; with a required activity result pending, completed release is not established.","Out-of-specification handling. FDA's May 2022 guidance calls repeated testing until a pass followed by disregarding the failures without scientific justification testing into compliance, which it describes as unscientific and objectionable under CGMP. It asks that the number of retests be set in advance in a procedure and not adjusted according to results, and it contrasts averages: initial 89 then 90 and 91 per cent averages 90 and tends to confirm the failure, while 80 then 85 and 105 also averages 90 but presents a very different picture. Releasing despite an initial failure that has not been invalidated should follow a full investigation. The guidance applies to chemistry-based laboratory testing of drugs regulated by CDER and says it is not intended to address biological assays, so it cannot simply be copied for a cell or potency assay.","Release is a quality decision. It is separate from regulatory authorisation of the product, a patient's eligibility and evidence of benefit, and a released stamp on a report does not answer those. For US licensed biological products, manufacturer release follows completion of applicable tests under 21 CFR 610.1. Separately, under 610.2 FDA may require samples and protocols and, on notification, bar distribution until the relevant CBER or CDER Director releases the lot. These are distinct manufacturer and official-release steps; this example does not establish other jurisdictions' rules.","A test on bulk or intermediate material concerns the material sampled at that process stage. FDA's January 1999 vaccine CMC guidance for licence applications separates drug substance from formulated bulk and finished product, with manufacturing, filling and finished-product sampling information. A pre-fill quality-control box in a diagram therefore does not by itself establish the identity, purity, potency or sterility of filled vials or final release. Apply the product's specified tests and quality review; the drawing supplies neither a universal test order nor release criteria."],"provenance":{"editedBy":"OnCo education audit","editedOn":"2026-11-10"},"category":"Regulation & policy"},"route":"/terms/batch-release/","neighbours":{"term":[{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/"},{"id":"good-manufacturing-practice","kind":"term","name":"Good manufacturing practice (GMP)","route":"/terms/good-manufacturing-practice/"},{"id":"platform-vs-personalized-components","kind":"term","name":"Platform and personalised components of a product","route":"/terms/platform-vs-personalized-components/"}],"technology":[{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"}]}}